Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT

医学 骨髓纤维化 移植 禁忌症 脾切除术 血栓形成 外科 内科学 门静脉血栓形成 脾脏 病理 骨髓 替代医学
作者
Nicola Polverelli,Juan Carlos Hernández‐Boluda,Tomasz Czerw,Tiziano Barbui,Mariella D’Adda,Hans Joachim Deeg,Markus Ditschkowski,Claire N. Harrison,Nicolaus Martin Kröger,Ruben A. Mesa,Francesco Passamonti,Francesca Palandri,Naveen Pemmaraju,Uday Popat,Damiano Rondelli,Alessandro Maria Vannucchi,Srđan Verstovšek,Marie Robin,Antonio Colecchia,Luigi Grazioli
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:10 (1): e59-e70 被引量:60
标识
DOI:10.1016/s2352-3026(22)00330-1
摘要

Splenomegaly is a hallmark of myelofibrosis, a debilitating haematological malignancy for which the only curative option is allogeneic haematopoietic cell transplantation (HCT). Considerable splenic enlargement might be associated with a higher risk of delayed engraftment and graft failure, increased non-relapse mortality, and worse overall survival after HCT as compared with patients without significantly enlarged splenomegaly. Currently, there are no standardised guidelines to assist transplantation physicians in deciding optimal management of splenomegaly before HCT. Therefore, the aim of this Position Paper is to offer a shared position statement on this issue. An international group of haematologists, transplantation physicians, gastroenterologists, surgeons, radiotherapists, and radiologists with experience in the treatment of myelofibrosis contributed to this Position Paper. The key issues addressed by this group included the assessment, prevalence, and clinical significance of splenomegaly, and the need for a therapeutic intervention before HCT for the control of splenomegaly. Specific scenarios, including splanchnic vein thrombosis and COVID-19, are also discussed. All patients with myelofibrosis must have their spleen size assessed before allogeneic HCT. Myelofibrosis patients with splenomegaly measuring 5 cm and larger, particularly when exceeding 15 cm below the left costal margin, or with splenomegaly-related symptoms, could benefit from treatment with the aim of reducing the spleen size before HCT. In the absence of, or loss of, response, patients with increasing spleen size should be evaluated for second-line options, depending on availability, patient fitness, and centre experience. Splanchnic vein thrombosis is not an absolute contraindication for HCT, but a multidisciplinary approach is warranted. Finally, prevention and treatment of COVID-19 should adhere to standard recommendations for immunocompromised patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
东少完成签到,获得积分10
1秒前
1秒前
闫诗宇发布了新的文献求助10
1秒前
1秒前
2秒前
2秒前
Kieran完成签到,获得积分10
2秒前
哈哈哈发布了新的文献求助10
3秒前
3秒前
科研通AI6.2的应助被zuo20050727采纳,获得10
4秒前
4秒前
兮非完成签到,获得积分10
4秒前
6秒前
醉熏的断缘完成签到,获得积分20
6秒前
匆匆发布了新的文献求助10
6秒前
6秒前
7秒前
Murphy完成签到,获得积分10
7秒前
7秒前
yyay完成签到 ,获得积分10
8秒前
我谈完成签到,获得积分10
8秒前
烟花的应助被快乐的忆安采纳,获得20
9秒前
要成为猫精病主任医师完成签到,获得积分10
9秒前
9秒前
10秒前
11秒前
李健的应助被闫诗宇采纳,获得10
11秒前
11秒前
12秒前
Lucas的应助被顺利毕业采纳,获得10
12秒前
张张完成签到 ,获得积分10
12秒前
科目三的应助被meng采纳,获得10
13秒前
14秒前
强强发布了新的文献求助10
14秒前
14秒前
李铭烁完成签到 ,获得积分10
14秒前
15秒前
匆匆发布了新的文献求助10
15秒前
林洁佳发布了新的文献求助10
15秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193605
求助须知:如何正确求助?哪些是违规求助? 9579751
关于积分的说明 21867369
捐赠科研通 7793242
什么是DOI,文献DOI怎么找? 3437325
关于科研通互助平台的介绍 2560761
邀请新用户注册赠送积分活动 2484193